Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria

King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025. Diabetes Care. 1998;21:1414–31.

World Health Organisation. Diabetes mellitus fact sheet, Number 238. 2002. http://www.who.int/diabetes . Cited 13 Aug 2006.

Haffner SM, Lehto S, Ronnemma T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–34.

Russell RB, Valiyeva E, Roman SH, Pogach LM, Suh D, Safford MM. Hospitalization, nursing home admission and deaths attributable to diabetes. Diabetes Care. 2005;28:1611–7.

Beckman JA, Creager MQ, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287:2570–81.

Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. Br Med J. 2006;332:73–8.

Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782–7.

American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care. 1999;22:S27–31.

Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. JAMA. 1996;276:1409–15.

UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854–65.

Cohen FJ, Conklin JE, Neslusan CA, Song X. Recent antihyperglyceamic prescribing trends for US privately insured patients with type 2 diabetes. Diabetes Care. 2003;26(6):1847–51.

Turner RC, Cull CA, Fright V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies. JAMA. 1999;281:2005–12.

Defronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131:281–303.

Chuang LM, Tsai ST, Huang BY, Tai TY; Diabcare-Asia 1998 Study Group. The status of diabetes control in Asia- a cross-sectional survey of 24,317 patients with diabetes mellitus in 1998. Diabetes Med. 2002;19:978–85.

Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27(1):17–20.

Wong JS, Rahimah N. Glycemic control of diabetic patients in an urban primary health care setting in Sarawak: the Tanah Putch Health Centre experience. Med J Malaysia. 2004;59(3):411–7.

El-Kebbi IM, Gallina DL, Ziemer DC, et al. Diabetes in urban African-Americans. VI. Utility of fasting or random glucose in identifying poor glycemic control. Diabetes Care. 1998;21(4):501–7.

Ndububa DA, Erhabor GE. Diabetic mortalities in Ilesa, Nigeria: a retrospective study. Cent Afr J Med. 1994;40(10):28–9.

Puepet FH, Agaba EI, Chuhwak EK. Some metabolic abnormalities in type 2 diabetic patients in Jos, north central Nigeria. Niger J Med. 2003;12(4):193–7.

Alebiosu CO. Clinical diabetic neuropathy in a tropical African population. West Afr J Med. 2003;22(2):152–5.

Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care. 2004;27:2444–9.

Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care. 2001;24:683–9.

Sullivan PW, Morrato EH, Ghushehyan V, et al. Obesity, inactivity and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the US, 2000–2002. Diabetes Care. 2005;28:1599–603.

American Diabetes Association (ADA). Standard of medical care in diabetes. Diabetes Care. 2005;28:S10–20.

Barnett AH. Treating to goal: challenges of current management. Eur J Endocrinol. 2004;151:T3–7.

Harrower AD. Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 2000;22(4):313–20.

British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary, March 2005. London: BMJ Publishing Group and Royal Pharmaceutical Society of Great Britain; 2005.

American Society of Health-System Pharmacists/American Hospital Formulary Services (ASHP/AHFS). AHFS Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2002.

Wan Mohamad WB, Tun Fizi A, Ismail RB, Mafauzy M. Efficacy and safety of Single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus. Diabetes Res. 2000;49(2):93–9.

Marre M, Howlett H, Lehert P, Allavoine T. Improved glycemic control with metformin–glibenclamide combined tablet therapy in type 2 diabetic patients inadequately controlled on metformin. Diabet Med. 2002;19(8):673–80.

Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in amanged care organization: a comparison of monotherapy, combination therapy and fixed-dose combination therapy. Clin Ther. 2002;24(3):460–7.

Erasmus RT, Blanco B, Okesina AB, Gqweta Z, Matsha T. Assessment of glycemic control in stable type 2 black south African diabetics attending a peri-urban clinic. Postgrad Med J. 1999;75:603–6.

Kolawole BA, Adegbenro C, Ayoola ZO, Opebiyi B. Diabetes mellitus related treatment goals: awareness and attainment in the Ife-Ijesha zone of south-western Nigeria. Afr J Med Med Sci. 2005;34(4):389–94.

United Nation Development Programme (UNDP). Eye of the needle—Nigeria 2000. New York, USA: Human Development Reports; 2000.

Seltzer HS. Drug induced hypoglycemia. Endocrinol Metab Clin North Am. 1989;18:163–83.

Talabi OA. A questionnaire survey of senior house officers/registrars response to their training at University College Hospital, Ibadan. West Afr J Med. 2003;22(2):108–11.

Ndom RJE, Makanjuola AB. Perceived stress factors among resident doctors in a Nigerian teaching hospital. West Afr J Med. 2004;23(3):78–81.

Ajayi IO, Olumide EA, Oyediran O. Patient satisfaction with the services provided at a general outpatient clinic, Ibadan, Oyo state, Nigeria. Afr J Med Med Sci. 2005;34:133–40.

Glasgow RE, Strycker LA, Hampson SE, Ruggiero L. Personal model beliefs and social-environmental barriers related to diabetes self-management. Diabetes Care. 1997;20:556–61.

Day JL. Diabetic patients education: determinants of success. Diabetes Metab Res Rev. 2000;16(Supl 1):S70–4.

Campbell RK. Role of the pharmacists in diabetes management. Am J Health Syst Pharm. 2002;59(9):18–21.

Acheampong JW, Boateng KA, Eghan BA, Story P, Parry EHO, Tomlinson S. The impact of diabetes nurses in the Komfo Anokye Teaching Hospital, Ghana. Diabetes Int. 2000;10:81–3.

Berthoet N, Favrat B, Fallab-Stubi CL, Brunner HR, Burnier M. Why objective monitoring of compliance is important in management of hypertension. J Clin Hypertens. 2000;2:210–4.

Fodor GJ, Kotrec M, BacsKai K, et al. Is interview a reliable method to verify compliance with antihypertensive therapy? An international central-European study. J Hum Hypertens. 2005;23:1261–6.

Yusuff KB, Alabi A. Assessing patient adherence to anti-hypertensive drug therapy: can a structured pharmacist-conducted interview separate the wheat from the chaff? Int J Pharm Pract. 2007;15:295–300.